Home
Antibodies
Proteins
IVD Raw Materials
Assay Kits
ELISA Kits
KD/KO Validation
About Us
Enzymes

FGFR4 (Phospho-Tyr642) Antibody #11836

Review:
Datasheet PDF
add to favorites
Catalog No. Package Size Price Quantity
50ul $219.00
100ul $319.00
Availability:Yes
Total:
ADD TO CART
 
Datasheet Images Protocol
Description
  • Product NameFGFR4 (Phospho-Tyr642) Antibody
  • Host SpeciesRabbit
  • ClonalityPolyclonal
  • PurificationAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
  • ApplicationsWB,ELISA
  • Species ReactivityHuman, Mouse, Rat
  • SpecificityThe antibody detects endogenous levels of FGFR4 only when phosphorylated at tyrosine 642.
  • Immunogen TypePeptide-KLH
  • Immunogen DescriptionPeptide sequence around phosphorylation site of tyrosine 642(I-D-Y(p)-Y-K) derived from Human FGFR4 .
  • Target NameFGFR4
  • ModificationPhospho
  • Alternative Names    FGFR-4; CD_antigen=CD334; Fibroblast growth factor receptor 4; EC=2.7.10.1;
  • Accession No. Swiss-Prot#: P22455;
    NCBI Gene#: 2264;
    NCBI Protein#: NP_002002.3.
  • UniprotP22455
  • Gene ID2264;
  • SDS-PAGE MW 90kd
  • Concentration 1.0mg/ml
  • Formulation Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • Storage Store at -20˚C/1 year
Application Details
Background

Published Papers

Loss of E-cadherin Activates a Targetable IGF1R Pathway in Invasive Lobular Breast Carcinoma. In Mol Cancer Res on 2022 Sep 2 by Ashuvinee Elangovan, Jagmohan Hooda,et al..PMID:35665642, , (2022),
PMID: 35665642
Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. In Mol Cancer Res on 2022 Sep 2 by Ashuvinee Elangovan, Jagmohan Hooda, et al..PMID:35665642, , (2022),
PMID: 35665642
Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.In Oncol Rep on 2015 Nov by Lingling Hu , Lanxiang Cong.PMID:26323668, , (2015),
PMID: 26323668
Please let us know if you have published research using #11836 so that we can cite your reference.

Customer Reviews and Rankings

No comment
Total 0 results, divided into1 pages. First Prev Next Last

My Review

Username:Anonymous user
E-mail:
Ratings:
Content:
Verification code:captcha

Application

WBWestern Blotting

IHCImmunohistochemistry

IFImmunofluorescence

ICCImmunocytochemistry

FCFlow Cytometry

IPImmunoprecipitation

EELISA

DBDot Blotting

ChIPChromatin Immunoprecipitation

GICAGold Immunochromatography Assay

NCNegative Control

Species Reactivity

HuHuman

MsMouse 

RtRat 

Dm Drosophila melanogaster

C Caenorhabditis elegans

MkMonkey

RbRabbit

B Bovine 

D Dog

PPig

HmHamster

ChHm Chinese Hamster 

ChkChicken  

ShpSheep